retatrutide triple agonist obesity trial Experimental drug cut weight by nearly 30% in Phase 3 trials, outperforming approved therapies, Eli Lilly says retatrutide triple agonist glp-1 gip

GLP-1 research spans a remarkably broad range of biological systems owing to the widespread distribution of the GLP-1 receptor across multiple tissue types

GLP-1, GIP, exendin-4 and liraglutide had suppressive effects on oxLDL-induced foam cell formation, which is linked with the suppression of infiltrated macrophage foam cells in atherosclerotic plaques, resulting in repressed atherosclerotic plaque formation

[1] Persistent nausea and vomiting : Especially if preventing adequate fluid or medication intake

GIP as a therapeutic target in diabetes and obesity: Insight from incretin co-agonists

These results align with emerging evidence of GSK3 as a target in cardiac mitochondrial dysfunction

But if her insurance approves the brand name, her monthly cost could drop to as little as $25